A study from the University of Chicago showed a new way to target previously “undruggable” proteins involved in cancer by ...

Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor regulated at the protein level by oxygen and iron. Under normoxic conditions HIF is degraded, but under hypoxic conditions or ...

It seems that proteins called hypoxia-inducible factors (HIFs) can affect gene expression in low-oxygen conditions. While some control of gene expression is mediated through control of whether a ...

It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by ...

Targeted therapies for kidney cancer include anti-angiogenesis therapies, which stops the process of making new blood vessels; mTOR inhibitors, that target mTOR to slow kidney cancer growth; and HIF2a ...

Elucidation of the roles of additional factors, especially local hypoxia-inducible factors such as HIF1 and pVHL, might give new insights into renal erythropoietin regulation and ultimately lead ...

Van Meir has developed novel therapeutic approaches for cancer using oncolytic adenoviruses and anti-angiogenic molecules and is currently developing novel small molecule inhibitors of the ...

Exelixis, Inc. EXEL entered into a clinical development collaboration agreement with pharma giant Merck MRK to advance the ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...

Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...

Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was ...

The Indian Council of Medical Research (ICMR) on Monday announced a partnership with domestic pharma giant Zydus Lifesciences ...